{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/bipolar-disorder/management/women-of-childbearing-age/","result":{"pageContext":{"chapter":{"id":"7cd1d695-071f-5e74-945f-e61927a44a85","slug":"women-of-childbearing-age","fullItemName":"Scenario: Women of childbearing age","depth":2,"htmlHeader":"<!-- begin field fcd29b72-d20a-4580-aeaa-7021dd060d04 --><h2>Scenario: Women of childbearing age</h2><!-- end field fcd29b72-d20a-4580-aeaa-7021dd060d04 -->","summary":"Covers the management of a woman with bipolar disorder planning a pregnancy, presenting with an unplanned pregnancy, presenting with an acute episode in pregnancy, or planning to breastfeed.","htmlStringContent":"<!-- begin item 8ac133ff-9b40-4176-9e9b-c42ffb0b526b --><!-- begin field 7249959c-e92d-4229-9b21-acd900ac0989 --><p>From age 14 years to 55 years (Female).</p><!-- end field 7249959c-e92d-4229-9b21-acd900ac0989 --><!-- end item 8ac133ff-9b40-4176-9e9b-c42ffb0b526b -->","topic":{"id":"ac644ce3-3932-5e1f-8676-4ebcfb5f240d","topicId":"87d084eb-bc7f-45b7-9384-f490e6417d9d","topicName":"Bipolar disorder","slug":"bipolar-disorder","lastRevised":"Last revised in February 2021","chapters":[{"id":"3ed6a7a1-589c-57a9-89fd-e61f76a4c198","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"96f8d073-2e2b-55bd-9f94-a0cf336756a7","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"5a048129-7c1e-5fc5-8a8a-3e91b2be7e18","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"61d98476-085c-58c4-b646-093d1564a66c","slug":"changes","fullItemName":"Changes"},{"id":"e8e86070-9a3a-5b97-8a3b-d76771dd7e92","slug":"update","fullItemName":"Update"}]},{"id":"308f8462-ca53-5dee-9a6a-463a88283762","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"e56ddcf1-8ade-5c55-ada8-cd9307fa9d45","slug":"goals","fullItemName":"Goals"},{"id":"c9a278dc-a960-595c-90fa-702a979fe434","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"6c858f7e-b8a9-5125-9b30-d15ff9489c89","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"caccf5a3-718b-556f-a3d7-e412c84fffec","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"1d1a32a6-8f9b-54ef-8db8-35685fd71f28","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"31f4b1ea-76e5-5273-821f-7ba3fd77ac0e","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"b529213a-3211-53f9-b870-f03b9a1d30c9","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"53fd9729-258a-5bc1-ac8d-c7c2ebdfd92e","slug":"definition","fullItemName":"Definition"},{"id":"0dc41761-cd41-54cc-8277-c96320874497","slug":"causes","fullItemName":"Causes"},{"id":"2c7c3452-f7d6-5a4d-ac13-72ecad737a44","slug":"incidence-prevalence","fullItemName":"Incidence and prevalence"},{"id":"7a53a39d-073b-5a29-b48d-a0ff3049049e","slug":"complications","fullItemName":"Complications"},{"id":"ae1afd6c-efdb-5d1f-82a9-ee9a07103bde","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"45d991bb-5121-511b-a201-826c8297a59d","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"ff54cf2c-7ebb-58b5-a77c-a285db95f263","slug":"suspecting-bipolar-disorder","fullItemName":"Suspecting bipolar disorder"},{"id":"a5cf6d30-ba09-58fa-b2a2-78490ef3dfe6","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"0c45d8c8-9038-5e75-9637-34b9b70a708f","fullItemName":"Management","slug":"management","subChapters":[{"id":"08d1a671-233b-56fe-9343-455ae9d9457c","slug":"primary-care-management","fullItemName":"Scenario: Primary care management"},{"id":"3168933b-1d1b-56e0-82d5-13b7a4175ed1","slug":"managing-relapse","fullItemName":"Scenario: Managing relapse"},{"id":"7fd5675a-5f41-5662-86a1-dcd7103d1e7b","slug":"routine-bipolar-disorder-review","fullItemName":"Scenario: Routine bipolar disorder review"},{"id":"7cd1d695-071f-5e74-945f-e61927a44a85","slug":"women-of-childbearing-age","fullItemName":"Scenario: Women of childbearing age"}]},{"id":"7be9863d-b620-5545-b0ca-d2a5ea14af95","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"d0da96ab-51ae-530a-ac52-76b445fb10a5","slug":"ssris","fullItemName":"SSRIs"},{"id":"7ccedc62-ec67-54d4-a721-f520c7573553","slug":"antipsychotics","fullItemName":"Antipsychotics"},{"id":"587e9545-d869-5933-b101-2407ad59bc52","slug":"lamotrigine","fullItemName":"Lamotrigine"},{"id":"f1925178-1888-5bf8-8868-92a526afff0f","slug":"lithium","fullItemName":"Lithium"},{"id":"1933741e-2f27-57bf-92f1-5d769518344f","slug":"valproate","fullItemName":"Valproate"}]},{"id":"1913037b-d494-5a34-be7c-baf4cb96acd4","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"88a92260-20b8-51eb-8b46-3a2409ddf63b","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"438d8ad5-e57e-58be-8902-0a3160dc221d","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"a4449bc7-d64d-5a1c-a07a-b9a548cc3172","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"be352ccd-5a94-556d-b076-f450b54edbfb","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"999ad09a-2f9f-562d-9583-938295801e7f","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"a2be53e8-c67a-5bbd-a684-a352c46d9902","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"c4e156df-5e61-50f0-bcf6-60433f5a4e37","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"0c45d8c8-9038-5e75-9637-34b9b70a708f","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"9465412f-1480-537c-a32a-38d18571ebf3","slug":"pregnancy-planned-or-unplanned","fullItemName":"Pregnancy (planned or unplanned)","depth":3,"htmlHeader":"<!-- begin field 32d6d811-fe18-4fb3-91f2-df497ccfc0b2 --><h3>How should I manage a woman with bipolar disorder who is planning a pregnancy or presents with an unplanned pregnancy?</h3><!-- end field 32d6d811-fe18-4fb3-91f2-df497ccfc0b2 -->","summary":null,"htmlStringContent":"<!-- begin item 14491cb1-0f4c-4e49-b212-b8cb00495aec --><!-- begin field 4a1569c6-d27d-4400-b21b-03ec7871c2d2 --><ul><li><strong>Refer women who are pregnant or planning a pregnancy to a specialist perinatal mental health service if available, or to the community mental health service for an assessment and discussion of drug treatment.</strong><ul><li><strong>Note: NICE recommends that if women or young girls of childbearing potential are already taking valproate they should be advised to gradually stop the medicine because of the risk of fetal malformations and adverse neurodevelopmental outcomes after any exposure in pregnancy</strong>. The dose of valproate should be reduced gradually over at least 4 weeks to minimise the risk of relapse. </li></ul></li><li><strong>Do not alter or stop drug treatment without seeking specialist advice.</strong><ul><li>Explain to the woman that she may be advised to:<ul><li>Remain on her current drug treatment throughout conception, pregnancy, and birth.</li><li>Switch to another drug treatment.</li><li>Stop or reduce the dose of her medication.</li></ul></li><li>Explain that the strategy which is chosen will depend on her wishes, and on the advice of the medical team who need to balance the risks of under-treatment (relapse) with the risk of harming the fetus by remaining on drug treatment.</li><li>Discuss the likelihood that sleep and routine will be disturbed after the baby is born. Participate in multi-agency plans for practical support after the baby is born (from the woman's family, health visitor, organizations such as Sure Start, and social care) so that the woman gets enough rest and sleep.</li></ul></li><li><strong>Note: the Medicines and Healthcare Products Regulatory Agency (MHRA) recommends that valproate should <em>not</em> be prescribed to female children, female adolescents, women of childbearing potential, or pregnant women to treat bipolar disorder unless the illness is very severe and there is no effective alternative option. Females of childbearing potential taking valproate should be enrolled in a pregnancy prevention plan. Valproate is a teratogen and can cause physical birth defects and developmental disorders in children exposed <em>in utero</em>.</strong><ul><li>The MHRA has produced a <a data-hyperlink-id=\"caa4f6f1-0ec7-4ab1-8a55-a98c00d0328a\" href=\"https://www.gov.uk/government/publications/toolkit-on-the-risks-of-valproate-medicines-in-female-patients\">toolkit</a> to help healthcare professionals advise women about the risks of taking valproate during pregnancy. </li><li>The available communication tools to support discussions with women on the risks of taking valproate in pregnancy include a healthcare professional <a data-hyperlink-id=\"420b5541-f087-4a52-8a92-a98c00d032a3\" href=\"http://www.medicines.org.uk/emc/RMM.420.pdf\">booklet</a>, a <a data-hyperlink-id=\"ac001fa1-7684-4a52-bee2-a98c00d032e7\" href=\"http://www.medicines.org.uk/emc/RMM.423.pdf\">consultation checklist</a>, as well as a <a data-hyperlink-id=\"6c9fe68f-c653-40b6-a7a5-a98c00d0332b\" href=\"http://www.medicines.org.uk/emc/RMM.421.pdf\">guide</a> and <a data-hyperlink-id=\"7ff115c0-f998-4e5d-b48a-a98c00d03384\" href=\"http://www.medicines.org.uk/emc/RMM.422.pdf\">card</a> to give to women who are taking valproate. A freely available patient information leaflet on <a data-hyperlink-id=\"7ca1c1e2-4275-4c95-85a0-aa9101006d7f\" href=\"http://www.medicinesinpregnancy.org/Medicine--pregnancy/Valproic-acid/\">use of valproate in pregnancy</a> is available from the UK teratology information service.</li></ul></li><li><strong>For women who are planning a pregnancy, give general pre-conception advice (such as cessation of smoking and alcohol consumption) and prescribe folic acid. Note that high dose (5 mg/day) is indicated in women taking certain medications and who are obese.</strong><ul><li>For more detailed information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/pre-conception-advice-management/\">Pre-conception - advice and management</a>.</li></ul></li></ul><style type=\"text/css\">//<![CDATA[//<![CDATA[p.p1 {margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px}p.p2 {margin: 0.0px 0.0px 0.0px 0.0px; font: 10.0px Helvetica}//]]>////]]>//</style><style type=\"text/css\">//<![CDATA[//<![CDATA[p.p1 {margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px}p.p2 {margin: 0.0px 0.0px 0.0px 0.0px; font: 10.0px Helvetica}//]]>////]]>//</style><!-- end field 4a1569c6-d27d-4400-b21b-03ec7871c2d2 --><!-- end item 14491cb1-0f4c-4e49-b212-b8cb00495aec -->","subChapters":[{"id":"51b2b32b-6e15-59b7-89be-523b296aaf3d","slug":"basis-for-recommendation-fe2","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 26b74ff6-557f-4806-a89b-a200ad4ec24c --><h4>Basis for recommendation</h4><!-- end field 26b74ff6-557f-4806-a89b-a200ad4ec24c -->","summary":null,"htmlStringContent":"<!-- begin item fe2b029e-c303-40c0-8d15-a09163f1b1d6 --><!-- begin field 0e4a3b3e-42db-444d-9b37-f52ece0d8a85 --><h5>Referral</h5><ul><li>The National Institute for Health and Care Excellence (NICE) recommends that woman with bipolar disorder who are pregnant or planning a pregnancy and who are being managed solely in primary care are re-referred to secondary care [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bipolar-disorder/references/\">NICE, 2018a</a>]. The recommendation to make a referral to perinatal mental health service (where available), or otherwise to community mental health services is pragmatic, based on what CKS considers to be good clinical practice. Specialist input is required but the local availability of specific perinatal psychiatric services is variable. The information relating to discussions risk:benefit assessment of stopping drug treatment, switching treatment, or altering the dose is pragmatic, based on what CKS, and the UK Teratology Information Service consider to be good clinical practice.</li></ul><h5>Valproate</h5><ul><li>The information that valproate should not be prescribed to female children, female adolescents, women of childbearing potential or pregnant women unless other treatments are ineffective or not tolerated, and should only be prescribed if a pregnancy prevention plan is in place, is based on advice from the Medicines and Healthcare Products Regulatory Agency (MHRA) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bipolar-disorder/references/\">MHRA, 2019</a>] and the Royal College of Obstetricians and Gynaecologists [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bipolar-disorder/references/\">Royal College of Obstetricians and Gynaecologists (RCOG), 2019</a>].</li><li>The information that women or young girls of childbearing potential who are already taking valproate should be advised to gradually stop the medicine because of the risk of fetal malformations and adverse neurodevelopmental outcomes after any exposure in pregnancy is based on updated NICE guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bipolar-disorder/references/\">NICE, 2020a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bipolar-disorder/references/\">NICE, 2020b</a>].  </li></ul><h5>Sleep routine, pre-conception advice</h5><ul><li>The advice that women who are pregnant or considering a pregnancy should be offered information about likely effects on their sleep routine and general pre-conception advice is pragmatic, based on what CKS considers to be good clinical practice.</li></ul><!-- end field 0e4a3b3e-42db-444d-9b37-f52ece0d8a85 --><!-- end item fe2b029e-c303-40c0-8d15-a09163f1b1d6 -->","subChapters":[]}]},{"id":"1226704f-6118-5258-8ab5-2e10c485f047","slug":"breastfeeding","fullItemName":"Breastfeeding","depth":3,"htmlHeader":"<!-- begin field 2c539f74-87f0-4df0-bc87-7ff200e9b573 --><h3>What issues should I consider if a woman is breastfeeding?</h3><!-- end field 2c539f74-87f0-4df0-bc87-7ff200e9b573 -->","summary":null,"htmlStringContent":"<!-- begin item 4b5ed7e7-f59b-40d9-aa6a-5f33951feb2d --><!-- begin field 7c65dfc7-1387-48a2-9033-546505de8f40 --><ul><li><strong>Support a woman with bipolar disorder in the choice of feeding method that best suits her and her family. </strong>Breastfeeding may be appropriate unless the woman is taking lithium (note: breastfeeding is also not advised in women taking carbamazepine or clozapine but these are rarely used to treat bipolar disorder).</li><li><strong>If more advice on breastfeeding and medication is required, </strong>liaise with specialist mental health services or seek specialist advice from the UK Drugs in Lactation Advisory Service: telephone 0121 311 1974, or 0121 378 2211.</li></ul><!-- end field 7c65dfc7-1387-48a2-9033-546505de8f40 --><!-- end item 4b5ed7e7-f59b-40d9-aa6a-5f33951feb2d -->","subChapters":[{"id":"248d16c6-167f-5233-ad32-5d58670573cb","slug":"basis-for-recommendation-ed8","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 894b1ff9-848a-49c3-96cb-e4a6c05d9cea --><h4>Basis for recommendation</h4><!-- end field 894b1ff9-848a-49c3-96cb-e4a6c05d9cea -->","summary":null,"htmlStringContent":"<!-- begin item ed83fa08-dc29-421d-958b-9a71bfc1a019 --><!-- begin field 860ea7ee-f91c-47a3-8588-2adc5ad58256 --><h5>Drugs contraindicated for breastfeeding</h5><ul><li>The information on drugs contraindicated for breastfeeding is based on expert opinion in the National Institute of Health and Care Excellence (NICE) guideline <em>Antenatal and postnatal mental health: clinical management and service guidance</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bipolar-disorder/references/\">NICE, 2018c</a>]. Note that there are no specific recommendations relating to the use of valproate and breastfeeding because NICE states that 'valproate is not recommended to treat a mental health problem in women of childbearing potential'.</li></ul><h5>Advice on breastfeeding</h5><ul><li>The advice to contact the UK Drugs in Lactation Advisory Service or to liaise with specialist mental health services to assess any risk posed to the infant by breastfeeding when taking medication for bipolar disorder is pragmatic, based on what CKS considers to be good clinical practice. </li></ul><!-- end field 860ea7ee-f91c-47a3-8588-2adc5ad58256 --><!-- end item ed83fa08-dc29-421d-958b-9a71bfc1a019 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}